The registration under the new G.S.R 581(E) regulation reflects Parexel’s commitment to regulatory compliance and clinical research excellence in India
Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, announced the successful completion of its Clinical Research Organization (CRO) registration with the Central Drugs Standard Control Organization (CDSCO). This registration complies with the new G.S.R 581 (E) regulation, which mandates all CROs operating in India to register with CDSCO.
Sanjay Vyas, President and MD, Parexel India and Global Strategic Business Unit Head for Clinical Logistics & Global Safety Services, said, “This registration reflects our ongoing commitment to meeting regulatory requirements and upholding the highest standards in clinical research. This registration enables us to continue supporting our customers in bringing life-saving treatments to patients safely and efficiently.”
